Eli Lilly and Co LLY · USD
Health Care · Pharmaceuticals · US listing · 🇺🇸 United States
S&P 500
1,354.00
-0.79%
Close of 6 Nov 2026, in USD
About Eli Lilly and Co
From its filings with the US Securities and Exchange Commission
Eli Lilly and Co is based in Indianapolis, Indiana and is incorporated in Indiana. Its shares trade on NYSE under the ticker LLY. It is a member of the S&P 500. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $65.18bn and net income of $20.64bn. At that date it held total assets of $112.48bn and shareholders' equity of $26.54bn.
Eli Lilly and Company (referred to as the company, Lilly, we, or us) was incorporated in 1901 in Indiana to succeed to the drug manufacturing business founded in Indianapolis, Indiana, in 1876 by Colonel Eli Lilly. We discover, develop, manufacture, and market products in a single business segment—human pharmaceutical products.
Our purpose is to unite caring with discovery to create medicines that make life better for people around the world. Our long-term success depends on our ability to continually discover or acquire, develop, and commercialize innovative medicines.
We manufacture and distribute our products through facilities in the United States (U.S.), including Puerto Rico, and in Europe and Asia. Our products are sold in approximately 90 countries.
In collaboration with Boehringer Ingelheim, a long-acting human insulin analog for the treatment of diabetes.
In collaboration with Boehringer Ingelheim, for the treatment of type 2 diabetes; to reduce the risk of cardiovascular death in adult patients with type 2 diabetes and established cardiovascular disease; to reduce the risk of cardiovascular death and hospitalizations for heart failure in adults; and to reduce the risk of sustained decline in estimated glomerular filtration rate (eGFR), end-stage kidney disease, cardiovascular death and hospitalization in adults with chronic kidney disease (CKD) at risk of progression.
Quoted from its 10-K, filed 12 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 9 Jul 1970
- Employees
- 50,000
- Website
- lilly.com ↗
- Head office
- LILLY CORPORATE CTR, INDIANAPOLIS, IN, 46285
- Incorporated in
- IN
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Lucas MontarceChief Financial Officer, Executive Vice President$2.9m
- Mr. Eric DozierExecutive Vice President, Chief People Officer
- Mr. Diogo RauExecutive Vice President, Chief Information and Digital Officer$5.1m
- Dr. Daniel SkovronskyExecutive Vice President, Chief Scientific Officer and President - Lilly Research Laboratories and Lilly Immunology$12.6m
- Ms. Anat HakimExecutive Vice President, General Counsel, Secretary$7.5m
- Mr. Edgardo HernandezExecutive Vice President, President - Manufacturing Operations
- Mr. Patrik JonssonExecutive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA$3.9m
- Ms. Melissa SeymourExecutive Vice President - Global Quality
- Mr. Jacob Van NaardenExecutive Vice President, President - Lilly Oncology$5.8m
- Ms. Anne WhiteExecutive Vice President, President - Lilly Neuroscience
- Mr. Ilya YuffaExecutive Vice President, President of Lilly International
- Mr. Juan LucianoLead Independent Director$398,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 65
- Environment
- 79
- Social
- 86
- Governance
- 29
- Direct emissions (scope 1)
- 192,000 t
- Energy emissions (scope 2)
- 396,000 t
- Value chain emissions (scope 3)
- 5,139,500 t
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Eli Lilly and Co has a strong global presence in the pharmaceutical industry, with a wide range of innovative and diverse product portfolio.
- The company has a strong research and development (R&D) capability, investing heavily in cutting-edge technology and scientific advancements.
- Eli Lilly has a strong brand reputation and is recognized for its commitment to quality and patient safety.
Weaknesses
- Eli Lilly faces significant competition from other pharmaceutical companies, which could impact its market share and profitability.
- The company is heavily reliant on a few key products for its revenue, leaving it vulnerable to patent expirations and generic substitutions.
- Eli Lilly has faced regulatory challenges in the past, which could impact its ability to gain approval for new products and expand into new markets.
Opportunities
- The increasing demand for personalized medicine and advancements in biotechnology present opportunities for Eli Lilly to develop targeted therapies for various diseases.
- Expansion into emerging markets, such as China and India, provides a significant growth opportunity for the company.
- Partnerships and collaborations with academic institutions and other pharmaceutical companies can enhance Eli Lilly's R&D capabilities and accelerate innovation.
Threats
- The pharmaceutical industry is highly regulated, and changes in government regulations could impact Eli Lilly's operations and profitability.
- The emergence of new competitors and the potential entry of tech giants into the healthcare industry pose threats to Eli Lilly's market position.
- There is always a risk of unexpected adverse events or negative clinical trial results, which could impact the company's reputation and financial performance.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.